Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Benitec Biopharma (BNTC) Accumulated Depreciation & Amortization (2019 - 2025)

Benitec Biopharma has reported Accumulated Depreciation & Amortization over the past 7 years, most recently at $1.5 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $1.5 million for Q4 2025, up 3738.46% from a year ago — trailing twelve months through Dec 2025 was $1.5 million (up 3738.46% YoY), and the annual figure for FY2025 was $66000.0, down 24.14%.
  • Accumulated Depreciation & Amortization reached $1.5 million in Q4 2025 per BNTC's latest filing, up from $13000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $1.5 million in Q4 2025 and bottomed at $13000.0 in Q3 2025.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $74500.0 (2022), compared with a mean of $156600.0.
  • The largest annual shift saw Accumulated Depreciation & Amortization tumbled 78.26% in 2024 before it surged 3738.46% in 2025.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $107000.0 in 2021, then decreased by 22.43% to $83000.0 in 2022, then plummeted by 56.63% to $36000.0 in 2023, then grew by 8.33% to $39000.0 in 2024, then soared by 3738.46% to $1.5 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for BNTC at $1.5 million in Q4 2025, $13000.0 in Q3 2025, and $66000.0 in Q2 2025.